Your session is about to expire
← Back to Search
Chemotherapy + Filgrastim for Bladder Cancer
Study Summary
This trial is studying how well combination chemotherapy with gemcitabine and docetaxel works when given with filgrastim in treating patients with urothelium cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Find a Location
Who is running the clinical trial?
Media Library
- I am not receiving any other chemotherapy treatments.I am not on any other biological treatments or receiving white blood cell transfusions.My cancer is a type of bladder cancer that cannot be cured with surgery or radiation.My cancer is not purely squamous cell or adenocarcinoma.I have never been treated with gemcitabine or docetaxel.My liver function tests are within the required limits.My blood counts meet the required levels and I don't have a bleeding disorder.I have not used experimental drugs or treatments, and I don't take acetaminophen to prevent fever.My cancer has not spread to my brain.I am over 18 years old.My cancer has spread after bladder and prostate removal surgery.I am mostly independent and active.My creatinine level is 2.0 mg/dL or lower.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are volunteers still being accepted for this research project?
"Unfortunately, this particular clinical trial is not currently looking for new participants. This information can be found on clinicaltrials.gov, which also indicates that the last update to this study was on December 3rd, 2013. Although this study is no longer active, there are 635 other trials that are still recruiting patients."
Has this medication been cleared for general use by the FDA?
"This particular Phase 2 trial lacks evidence of efficacy, but there is some data supporting the safety of the proposed treatment. Consequently, our team at Power rated this a 2."
Is this study taking place at many different locations throughout the United States?
"Currently, this trial is underway at 13 total locations. These are: Center for Hematology-Oncology in Boca Raton, Florida; St. Joseph Medical Center in Towson, Maryland; Memphis Cancer Center, Inc. in Memphis, Tennessee; and 10 other sites."
Share this study with friends
Copy Link
Messenger